Healthcare >> CEO Interviews >> October 17, 2003
JOSEPH A. MOLLICA is the Chairman, President and Chief Executive Officer
of Pharmacopeia, Inc., a Princeton, New Jersey-based company engaged in
the field of research to discover low molecular weight drug compounds
using combinatorial chemistry and automated high throughput screening.
Through its software division, Accelrys, Pharmacopeia provides modeling
and simulation software, cheminformatics and bioinformatics to the
pharmaceutical and chemical industries. From 1987 to 1993, Dr. Mollica
was employed by the DuPont Company and then by the DuPont Merck
Pharmaceutical Company where, from 1991 to 1993, he served as President
and Chief Executive Officer and previously as Vice President, Medical
Products for DuPont. At Ciba-Geigy, where he was employed from 1966 to
1986, he served in a variety of positions of increasing responsibility,
rising to Senior Vice President of Ciba-Geigy's Pharmaceutical Division.
Dr. Mollica is currently on the Boards of Pharmacopeia, Inc., Genencor
International Inc., Impath, Inc., and Neurocrine Biosciences. He
received his BS from the University of Rhode Island and his MS and PhD
from the University of Wisconsin and ScD, h.c. from the University of
Rhode Island. Profile
over the past year or so that investors should focus on?
Dr. Mollica: We released our first half results in July 2003. 75%
